Since 2017, treatment recommendations for patients with inoperable stage III NSCLC combine concurrent chemoradiotherapy with consecutive maintenance treatment with programmed cell death ligand 1 (PD-L1) inhibitor durvalumab. This evidence concerns the gene CD274 and non-small cell lung carcinoma.